{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"AVROBIO, Inc."},"Symbol":{"label":"Symbol","value":"AVRO"},"Address":{"label":"Address","value":"ONE KENDALL SQUARE BUILDING 300, SUITE 201, CAMBRIDGE, Massachusetts, 2139, United States"},"Phone":{"label":"Phone","value":"+1 617 914-8420"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.avrobio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Essra Ridha","title":"Chief Medical Officer"},{"name":"Geoff MacKay","title":"President, Chief Executive Officer &amp; Director"},{"name":"Kim Raineri","title":"Chief Manufacturing &amp; Technical Operations Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}